Market Research Logo

Cell Line Development Market Size By Product (Reagents & Media, Equipment {Incubator, Centrifuge, Bioreactor, Storage Equipment, Microscope}, Accessories & Consumables), By Source (Mammalian, Non-Mammalian {Insects, Amphibians}), By Cell Line (Recombinant

Cell Line Development Market Size By Product (Reagents & Media, Equipment {Incubator, Centrifuge, Bioreactor, Storage Equipment, Microscope}, Accessories & Consumables), By Source (Mammalian, Non-Mammalian {Insects, Amphibians}), By Cell Line (Recombinant, Hybridomas, Continuous Cell Line, Primary Cell Line), By Application (Bioproduction, Drug Discovery, Toxicity Testing, Tissue Engineering, Research) Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, France, UK, Spain, Italy, Russia, Japan, China, India, South Korea, Australia, Brazil, Mexico, South Africa, Saudi Arabia), Application Potential, Competitive Market Share & Forecast, 2018 - 2024

Cell Line Development Market will reach over USD 7.5 billion by 2024; as per a new research report.

Increasing incidences of cancer coupled with growing demand for monoclonal antibodies and vaccines will drive cell line development market. Rising prevalence of cancer has become major healthcare concern globally, hence government and several other organizations are conducting extensive research to reduce disease burden one of such approach includes cancer cell line development.

High alcohol and tobacco consumption coupled with unhealthy food and physical inactivity will escalate number of cancer incidences. Growth of biotechnology sector will positively impact cell line development market growth. Biotechnology based applications of cell line industry includes cell culture, drug discovery and gene therapy will grow significantly in coming future.

Patent expiration of blockbuster biologics such as Neupogen leading to development of new biosimilars should increase demand for human and animal cell lines. Thereby, accelerating industry expansion. Technological advancements in cell line development including automated screening methods, disposable equipment, enriched medias, improved expression systems and monitoring processes will drive industry growth. However, stringent regulations along with various concerns associated with stem cell research will hamper industry growth over the coming years.

Reagents and media product segment dominated the industry in 2017 owing to high usage of reagents and media in tissue engineering, toxicity testing, research, bioproduction, development of regenerative medicine and others. It forms essential component for cell line development and cell culture procedures will drive industry growth. Non-mammalian source segment is estimated to grow considerably during the forecast period owing to high application in insecticide screening and toxicology study.

Advancement in rDNA technology has escalated demand for recombinant cell lines. Moreover, several applications of rDNA technology including production of various biological products such as enzymes, immunobiological, synthetic hormones and various other anti-cancer agents will drive recombinant cell line type segment during the forecast timeframe.

Based on application type, the industry is bifurcated into bioproduction, toxicity testing, drug discovery, tissue engineering and research. Tissue engineering segment will witness robust growth rate during the forecast period due to increasing investment in R&D coupled with rising demand for advanced cancer treatment.

U.S. cell line development market valued around USD 1.1 billion in 2017 and estimated to grow considerably during the forecast timeframe. Launch of sophisticated cell line development technologies, well-established healthcare infrastructure and large-scale production of protein therapeutics will drive the U.S. cell line development market during the forecast timeframe.

High incident rate of cancer, favorable reimbursement for biologics and rising demand for monoclonal antibodies, vaccines and gene therapy will drive France cell line development market over the coming years. Presence of associations such as The French National Cancer Institute (INCa) working towards reducing cancer prevalence will positively impact the industry growth.

Few notable industry players operating in cell line development market are GE Healthcare, Thermo Fisher Scientific, Lonza Group, Sigma-Aldrich Corporation (Merck), Cytovance Biologics, WuXi AppTec, Sartorius, Corning, Selexis, Vista Biologicals, EuBiologics, Paragon Bioservices, Cobra Biologics, Patheon, Samsung Biologics, NAEJA RGM Pharmaceuticals, GVK BIO, Catalent and others. Industry players are focusing towards expanding business portfolio to consolidate their market position as well as increase consumer base. For instance, In February 2017, Lonza entered into strategic partnership with Sanofi, that aimed at building mammalian cell facilities to produce monoclonal antibodies in Switzerland.


Data Tables
1.1. Methodology
1.2. Market definitions
1.3. Forecast parameters
1.4. Data Sources
1.4.1. Secondary
1.4.1.1.Paid Sources
1.4.1.2. Unpaid Sources
1.4.2. Primary
Data Tables
2.1. Cell line development industry 360 degree synopsis, 2013 - 2024
2.1.1. Business trends
2.1.2. Product trends
2.1.3. Source trends
2.1.4. Cell line type trends
2.1.5. Application trends
2.1.6. Regional trends
Data Tables
3.1. Industry segmentation
3.2. Industry landscape, 2013 - 2024
3.3. Industry impact forces
3.3.1. Growth drivers
3.3.1.1.Rise in production of vaccines globally
3.3.1.2.Increasing number of cancer incidences especially in developing countries such as India and China
3.3.1.3.Extended applications of biotechnology sector
3.3.1.4.Patent expiration of blockbuster biologics leading to innovations in the field
3.3.1.5.Escalating demand for monoclonal antibodies in U.S. and Europe
3.3.1.6. Technological advancements in cell line development
3.3.2. Industry pitfalls & challenges
3.3.2.1.Ambiguous regulatory landscape
3.3.2.2. Growing concerns related to stem cell research
3.4. Growth potential analysis
3.4.1. By product
3.4.2. By source
3.4.3. By cell line type
3.4.4. By application
3.5. Porter's analysis
3.6. Regulatory landscape
3.6.1. U.S.
3.6.2. Europe
3.6.3. China
3.7. Company landscape, 2017
3.7.1. Strategy dashboard
3.8. PESTEL analysis
Data Tables
4.1. Key segment trends
4.2. Reagents and media
4.2.1. Reagents and media market, by region, 2013 - 2024 (USD Million)
4.3. Equipment
4.3.1. Equipment market, by region, 2013 - 2024, (USD Million)
4.3.2. Incubators
4.3.2.1. Incubators market, by region, 2013 - 2024, (USD Million)
4.3.3. Centrifuges
4.3.3.1. Centrifuges market, by region, 2013 - 2024, (USD Million)
4.3.4. Bioreactors
4.3.4.1. Bioreactors market, by region, 2013 - 2024, (USD Million)
4.3.5. Storage equipment
4.3.5.1. Storage equipment market, by region, 2013 - 2024, (USD Million)
4.3.6. Microscopes
4.3.6.1. Microscopes market, by region, 2013 - 2024, (USD Million)
4.4. Accessories and consumables
4.4.1. Accessories and consumables market, by region, 2013 - 2024, (USD Million)
Data Tables
5.1. Key segment trends
5.2. Mammalian
5.2.1. Mammalian cell line development market, by region, 2013 - 2024, (USD Million)
5.3. Non-mammalian
5.3.1. Non-mammalian cell development market, by region 2013 - 2024, (USD Million)
5.3.2. Insects
5.3.2.1. Insect cell line development market, by region 2013 - 2024, (USD Million)
5.3.3. Amphibians
5.3.3.1. Amphibians cell line development market, by region 2013 - 2024, (USD Million)
Data Tables
6.1. Key segment trends
6.2. Recombinant cell lines
6.2.1. Recombinant cell line development market, by region, 2013 - 2024, (USD Million)
6.3. Hybridomas
6.3.1. Hybridomas cell line development market, by region, 2013 - 2024, (USD Million)
6.4. Continuous cell lines
6.4.1. Continuous cell line development market, by region, 2013 - 2024, (USD Million)
6.5. Primary cell lines
6.5.1. Primary cell line development market, by region, 2013 - 2024, (USD Million)
Data Tables
7.1. Key segment trends
7.2. Bioproduction market
7.2.1. Bioproduction market, by region, 2013 - 2024, (USD Million)
7.3. Drug discovery
7.3.1. Drug discovery market, by region, 2013 - 2024, (USD Million)
7.4. Toxicity testing
7.4.1. Toxicity testing market, by region, 2013 - 2024, (USD Million)
7.5. Tissue engineering
7.5.1. Tissue engineering market, by region, 2013 - 2024, (USD Million)
7.6. Research
7.6.1. Research market, by region, 2013 - 2024, (USD Million)
Data Tables
8.1. Key regional trends
8.2. North America
8.2.1. North America cell line development market, by region, 2013 - 2024 (USD Million)
8.2.2. North America cell line development market, by product, 2013 - 2024 (USD Million)
8.2.2.1. North America cell line development market, by equipment, 2013 - 2024 (USD Million)
8.2.3. North America cell line development market, by source, 2013 - 2024 (USD Million)
8.2.3.1. North America cell line development market, by non-mammalian source 2013 - 2024 (USD Million)
8.2.4. North America cell line development market, by type of cell lines, 2013 - 2024 (USD Million)
8.2.5. North America cell line development market, by application, 2013 - 2024 (USD Million)
8.2.6. U.S.
8.2.6.1. U.S. cell line development market, by product, 2013 - 2024 (USD Million)
8.2.6.1.1. U.S. cell line development market, by equipment, 2013 - 2024 (USD Million)
8.2.6.2. U.S. cell line development market, by source, 2013 - 2024 (USD Million)
8.2.6.2.1. U.S. cell line development market, by non-mammalian source 2013 - 2024 (USD Million)
8.2.6.3. U.S. cell line development market, by type of cell lines, 2013 - 2024 (USD Million)
8.2.6.4. U.S. cell line development market, by application, 2013 - 2024 (USD Million)
8.2.7. Canada
8.2.7.1. Canada cell line development market, by product, 2013 - 2024 (USD Million)
8.2.7.1.1. Canada cell line development market, by equipment, 2013 - 2024 (USD Million)
8.2.7.2. Canada cell line development market, by source, 2013 - 2024 (USD Million)
8.2.7.2.1. Canada cell line development market, by non-mammalian source 2013 - 2024 (USD Million)
8.2.7.3. Canada cell line development market, by type of cell lines, 2013 - 2024 (USD Million)
8.2.7.4. Canada cell line development market, by application, 2013 - 2024 (USD Million)
8.3. Europe
8.3.1. Europe cell line development market, by country 2013 - 2024 (USD Million)
8.3.2. Europe cell line development market, by product, 2013 - 2024 (USD Million)
8.3.2.1. Europe cell line development market, by equipment, 2013 - 2024 (USD Million)
8.3.3. Europe cell line development market, by source, 2013 - 2024 (USD Million)
8.3.3.1. Europe cell line development market, by non-mammalian source 2013 - 2024 (USD Million)
8.3.4. Europe cell line development market, by type of cell lines, 2013 - 2024 (USD Million)
8.3.5. Europe cell line development market, by application, 2013 - 2024 (USD Million)
8.3.6. Germany
8.3.6.1. Germany cell line development market, by product, 2013 - 2024 (USD Million)
8.3.6.1.1. Germany cell line development market, by equipment, 2013 - 2024 (USD Million)
8.3.6.2. Germany cell line development market, by source, 2013 - 2024 (USD Million)
8.3.6.2.1. Germany cell line development market, by non-mammalian source 2013 - 2024 (USD Million)
8.3.6.3. Germany cell line development market, by type of cell lines, 2013 - 2024 (USD Million)
8.3.6.4. Germany cell line development market, by application, 2013 - 2024 (USD Million)
8.3.7. France
8.3.7.1. France cell line development market, by product, 2013 - 2024 (USD Million)
8.3.7.1.1. France cell line development market, by equipment, 2013 - 2024 (USD Million)
8.3.7.2. France cell line development market, by source, 2013 - 2024 (USD Million)
8.3.7.2.1. France cell line development market, by non-mammalian source 2013 - 2024 (USD Million)
8.3.7.3. France cell line development market, by type of cell lines, 2013 - 2024 (USD Million)
8.3.7.4. France cell line development market, by application, 2013 - 2024 (USD Million)
8.3.8. UK
8.3.8.1. UK cell line development market, by product, 2013 - 2024 (USD Million)
8.3.8.1.1. UK cell line development market, by equipment, 2013 - 2024 (USD Million)
8.3.8.2. UK cell line development market, by source, 2013 - 2024 (USD Million)
8.3.8.2.1. UK cell line development market, by non-mammalian source 2013 - 2024 (USD Million)
8.3.8.3. UK cell line development market, by type of cell lines, 2013 - 2024 (USD Million)
8.3.8.4. UK cell line development market, by application, 2013 - 2024 (USD Million)
8.3.9. Spain
8.3.9.1. Spain cell line development market, by product, 2013 - 2024 (USD Million)
8.3.9.1.1. Spain cell line development market, by equipment, 2013 - 2024 (USD Million)
8.3.9.2. Spain cell line development market, by source, 2013 - 2024 (USD Million)
8.3.9.2.1. Spain cell line development market, by non-mammalian source 2013 - 2024 (USD Million)
8.3.9.3. Spain cell line development market, by type of cell lines, 2013 - 2024 (USD Million)
8.3.9.4. Spain cell line development market, by application, 2013 - 2024 (USD Million)
8.3.10. Italy
8.3.10.1. Italy cell line development market, by product, 2013 - 2024 (USD Million)
8.3.10.1.1. Italy cell line development market, by equipment, 2013 - 2024 (USD Million)
8.3.10.2. Italy cell line development market, by source, 2013 - 2024 (USD Million)
8.3.10.2.1. Italy cell line development market, by non-mammalian source 2013 - 2024 (USD Million)
8.3.10.3. Italy cell line development market, by type of cell lines, 2013 - 2024 (USD Million)
8.3.10.4. Italy cell line development market, by application, 2013 - 2024 (USD Million)
8.3.11. Russia
8.3.11.1. Russia cell line development market, by product, 2013 - 2024 (USD Million)
8.3.11.1.1. Russia cell line development market, by equipment, 2013 - 2024 (USD Million)
8.3.11.2. Russia cell line development market, by source, 2013 - 2024 (USD Million)
8.3.11.2.1. Russia cell line development market, by non-mammalian source 2013 - 2024 (USD Million)
8.3.11.3. Russia cell line development market, by type of cell lines, 2013 - 2024 (USD Million)
8.3.11.4. Russia cell line development market, by application, 2013 - 2024 (USD Million)
8.4. Asia Pacific
8.4.1. Asia Pacific cell line development market, by country, 2013 - 2024 (USD Million)
8.4.2. Asia Pacific cell line development market, by product, 2013 - 2024 (USD Million)
8.4.2.1. Asia Pacific cell line development market, by equipment, 2013 - 2024 (USD Million)
8.4.3. Asia Pacific cell line development market, by source, 2013 - 2024 (USD Million)
8.4.3.1. Asia Pacific cell line development market, by non-mammalian source 2013 - 2024 (USD Million)
8.4.4. Asia Pacific cell line development market, by type of cell lines, 2013 - 2024 (USD Million)
8.4.5. Asia Pacific cell line development market, by application, 2013 - 2024 (USD Million)
8.4.6. Japan
8.4.6.1. Japan cell line development market, by product, 2013 - 2024 (USD Million)
8.4.6.1.1. Japan cell line development market, by equipment, 2013 - 2024 (USD Million)
8.4.6.2. Japan cell line development market, by source, 2013 - 2024 (USD Million)
8.4.6.2.1. Japan cell line development market, by non-mammalian source 2013 - 2024 (USD Million)
8.4.6.3. Japan cell line development market, by type of cell lines, 2013 - 2024 (USD Million)
8.4.6.4. Japan cell line development market, by application, 2013 - 2024 (USD Million)
8.4.7. China
8.4.7.1. China cell line development market, by product, 2013 - 2024 (USD Million)
8.4.7.1.1. China cell line development market, by equipment, 2013 - 2024 (USD Million)
8.4.7.2. China cell line development market, by source, 2013 - 2024 (USD Million)
8.4.7.2.1. China cell line development market, by non-mammalian source 2013 - 2024 (USD Million)
8.4.7.3. China cell line development market, by type of cell lines, 2013 - 2024 (USD Million)
8.4.7.4. China cell line development market, by application, 2013 - 2024 (USD Million)
8.4.8. India
8.4.8.1. India cell line development market, by product, 2013 - 2024 (USD Million)
8.4.8.1.1. India cell line development market, by equipment, 2013 - 2024 (USD Million)
8.4.8.2. India cell line development market, by source, 2013 - 2024 (USD Million)
8.4.8.2.1. India cell line development market, by non-mammalian source 2013 - 2024 (USD Million)
8.4.8.3. India cell line development market, by type of cell lines, 2013 - 2024 (USD Million)
8.4.8.4. India cell line development market, by application, 2013 - 2024 (USD Million)
8.4.9. South Korea
8.4.9.1. South Korea cell line development market, by product, 2013 - 2024 (USD Million)
8.4.9.1.1. South Korea cell line development market, by equipment, 2013 - 2024 (USD Million)
8.4.9.2. South Korea cell line development market, by source, 2013 - 2024 (USD Million)
8.4.9.2.1. South Korea cell line development market, by non-mammalian source 2013 - 2024 (USD Million)
8.4.9.3. South Korea cell line development market, by type of cell lines, 2013 - 2024 (USD Million)
8.4.9.4. South Korea cell line development market, by application, 2013 - 2024 (USD Million)
8.4.10. Australia
8.4.10.1. Australia cell line development market, by product, 2013 - 2024 (USD Million)
8.4.10.1.1. Australia cell line development market, by equipment, 2013 - 2024 (USD Million)
8.4.10.2. Australia cell line development market, by source, 2013 - 2024 (USD Million)
8.4.10.2.1. Australia cell line development market, by non-mammalian source 2013 - 2024 (USD Million)
8.4.10.3. Australia cell line development market, by type of cell lines, 2013 - 2024 (USD Million)
8.4.10.4. Australia cell line development market, by application, 2013 - 2024 (USD Million)
8.5. Latin America
8.5.1. Latin America cell line development market, by country 2013 - 2024 (USD Million)
8.5.2. Latin America cell line development market, by product, 2013 - 2024 (USD Million)
8.5.2.1. Latin America cell line development market, by equipment, 2013 - 2024 (USD Million)
8.5.3. Latin America cell line development market, by source, 2013 - 2024 (USD Million)
8.5.3.1. Latin America cell line development market, by non-mammalian source 2013 - 2024 (USD Million)
8.5.4. Latin America cell line development market, by type of cell lines, 2013 - 2024 (USD Million)
8.5.5. Latin America cell line development market, by application, 2013 - 2024 (USD Million)
8.5.6. Mexico
8.5.6.1. Mexico cell line development market, by product 2013 - 2024 (USD Million)
8.5.6.1.1. Mexico cell line development market, by equipment, 2013 - 2024 (USD Million)
8.5.6.2. Mexico cell line development market, by source, 2013 - 2024 (USD Million)
8.5.6.2.1. Mexico cell line development market, by non-mammalian source 2013 - 2024 (USD Million)
8.5.6.3. Mexico cell line development market, by type of cell lines, 2013 - 2024 (USD Million)
8.5.6.4. Mexico cell line development market, by application, 2013 - 2024 (USD Million)
8.5.7. Brazil
8.5.7.1. Brazil cell line development market, by product 2013 - 2024 (USD Million)
8.5.7.1.1. Brazil cell line development market, by equipment, 2013 - 2024 (USD Million)
8.5.7.2. Brazil cell line development market, by source, 2013 - 2024 (USD Million)
8.5.7.2.1. Brazil cell line development market, by non-mammalian source 2013 - 2024 (USD Million)
8.5.7.3. Brazil cell line development market, by type of cell lines, 2013 - 2024 (USD Million)
8.5.7.4. Brazil cell line development market, by application, 2013 - 2024 (USD Million)
8.6. MEA
8.6.1. MEA cell line development market, by country 2013 - 2024 (USD Million)
8.6.2. MEA cell line development market, by product, 2013 - 2024 (USD Million)
8.6.2.1. MEA cell line development market, by equipment, 2013 - 2024 (USD Million)
8.6.3. MEA cell line development market, by source, 2013 - 2024 (USD Million)
8.6.3.1. MEA cell line development market, by non-mammalian source 2013 - 2024 (USD Million)
8.6.4. MEA cell line development market, by type of cell lines, 2013 - 2024 (USD Million)
8.6.5. MEA cell line development market, by application, 2013 - 2024 (USD Million)
8.6.6. South Africa
8.6.6.1. South Africa cell line development market, by product 2013 - 2024 (USD Million)
8.6.6.1.1.South Africa cell line development market, by equipment, 2013 - 2024 (USD Million)
8.6.6.2. South Africa cell line development market, by source, 2013 - 2024 (USD Million)
8.6.6.2.1.South Africa cell line development market, by non-mammalian source 2013 - 2024 (USD Million)
8.6.6.3. South Africa cell line development market, by type of cell lines, 2013 - 2024 (USD Million)
8.6.6.4. South Africa cell line development market, by application, 2013 - 2024 (USD Million)
8.6.7. Saudi Arabia
8.6.7.1. Saudi Arabia cell line development market, by product 2013 - 2024 (USD Million)
8.6.7.1.1.Saudi Arabia cell line development market, by equipment, 2013 - 2024 (USD Million)
8.6.7.2. Saudi Arabia cell line development market, by source, 2013 - 2024 (USD Million)
8.6.7.2.1.Saudi Arabia cell line development market, by non-mammalian source 2013 - 2024 (USD Million)
8.6.7.3. Saudi Arabia cell line development market, by type of cell lines, 2013 - 2024 (USD Million)
8.6.7.4. Saudi Arabia cell line development market, by application, 2013 - 2024 (USD Million)
Data Tables
9.1. GE Healthcare
9.1.1. Business Overview
9.1.2. Financial Data
9.1.3. Product Landscape
9.1.4. Strategic Outlook
9.1.5. SWOT Analysis
9.2. Thermo Fisher Scientific Inc.
9.2.1. Business Overview
9.2.2. Financial Data
9.2.3. Product Landscape
9.2.4. Strategic Outlook
9.2.5. SWOT Analysis
9.3. Lonza Group AG
9.3.1. Business Overview
9.3.2. Financial Data
9.3.3. Product Landscape
9.3.4. Strategic Outlook
9.3.5. SWOT Analysis
9.4. Sigma-Aldrich Corporation (Merck)
9.4.1. Business Overview
9.4.2. Financial Data
9.4.3. Product Landscape
9.4.4. Strategic Outlook
9.4.5. SWOT Analysis
9.5. Cytovance Biologics
9.5.1. Business Overview
9.5.2. Financial Data
9.5.3. Product Landscape
9.5.4. Strategic Outlook
9.5.5. SWOT Analysis
9.6. WuXi AppTec
9.6.1. Business Overview
9.6.2. Service Landscape
9.6.3. Strategic Outlook
9.6.4. SWOT Analysis
9.7. American Type Culture Collection
9.7.1. Business Overview
9.7.2. Product Landscape
9.7.3. Strategic Outlook
9.7.4. SWOT Analysis
9.8. Sartorius Stedim Biotech GmbH
9.8.1. Business Overview
9.8.2. Financial Data
9.8.3. Product Landscape
9.8.4. Strategic Outlook
9.8.5. SWOT Analysis
9.9. Corning Inc.
9.9.1. Business Overview
9.9.2. Financial Data
9.9.3. Product Landscape
9.9.4. Strategic Outlook
9.9.5. SWOT Analysis
9.10. Selexis SA
9.10.1. Business Overview
9.10.2. Product Landscape
9.10.3. Strategic Outlook
9.10.4. SWOT Analysis
9.11. Vista Biologicals Co.
9.11.1.Business Overview
9.11.2.Product Landscape
9.11.3.Strategic Outlook
9.11.4.SWOT Analysis
9.12. EuBiologics Co., Ltd.
9.12.1.Business Overview
9.12.2.Product Landscape
9.12.3.Strategic Outlook
9.12.4.SWOT Analysis
9.13. Paragon Bioservices
9.13.1.Business Overview
9.13.2.Service Landscape
9.13.3.Strategic Outlook
9.13.4.SWOT Analysis
9.14. Cobra Biologics
9.14.1.Business Overview
9.14.2.Service Landscape
9.14.3.Strategic Outlook
9.14.4.SWOT Analysis
9.15. Patheon
9.15.1.Business Overview
9.15.2.Financial Data
9.15.3.Product Landscape
9.15.4.Strategic Outlook
9.15.5.SWOT Analysis
9.16. Samsung Biologics
9.16.1.Business Overview
9.16.2.Financial Data
9.16.3.Product Landscape
9.16.4.Strategic Outlook
9.16.5.SWOT Analysis
9.17. NAEJA RGM Pharmaceuticals
9.17.1.Business Overview
9.17.2.Product Landscape
9.17.3.SWOT Analysis
9.18. GVK BIO
9.18.1.Business Overview
9.18.2.Financial Data
9.18.3.Product Landscape
9.18.4.Strategic Outlook
9.18.5.SWOT Analysis
9.19. Progenitor Cell Therapy (PCT)
9.19.1.Business Overview
9.19.2.Financial Data
9.19.3.Product Landscape
9.19.4.Strategic Outlook
9.19.5.SWOT Analysis
9.20. Apath LLC
9.20.1.Business Overview
9.20.2.Product Landscape
9.20.3.Strategic Outlook
9.20.4.SWOT Analysis
9.21. Cell for Cure
9.21.1.Business Overview
9.21.2.Financial Data
9.21.3.Product Landscape
9.21.4.Strategic Outlook
9.21.5.SWOT Analysis
9.22. Epistem Holdings Plc
9.22.1.Business Overview
9.22.2.Financial Data
9.22.3.Product Landscape
9.22.4.Strategic Outlook
9.22.5.SWOT Analysis
9.23. Catalent Inc.
9.23.1.Business Overview
9.23.2.Financial Data
9.23.3.Product Landscape
9.23.4.Strategic Outlook
9.23.5.SWOT Analysis
9.24. Bioceros
9.24.1.Business Overview
9.24.2.Product Landscape
9.24.3.Strategic Outlook
9.24.4.SWOT Analysis
9.25. Abzena PLC
9.25.1.Business Overview
9.25.2.Financial Data
9.25.3.Product Landscape
9.25.4.Strategic Outlook
9.25.5.SWOT Analysis
9.26. Promocell
9.26.1.Business Overview
9.26.2.Product Landscape
9.26.3.Strategic Outlook
9.26.4.SWOT Analysis
9.27. Cyagen
9.27.1.Business Overview
9.27.2.Product Landscape
9.27.3.SWOT Analysis
Data Tables
TABLE 1. Cell line development industry 360 degree synopsis, 2013 - 2024
TABLE 2. Global cell line development market, 2013 - 2024 (USD Mn)
TABLE 3. Global cell line development market, by product, 2013 - 2017 (USD Mn)
TABLE 4. Global cell line development market, by product, 2018 - 2024 (USD Mn)
TABLE 5. Global cell line development market, by source, 2013 - 2017 (USD Mn)
TABLE 6. Global cell line development market, by source, 2018 - 2024 (USD Mn)
TABLE 7. Global cell line development market, by type of cell lines, 2013 - 2024 (USD Mn)
TABLE 8. Global cell line development market, by type of cell lines, 2013 - 2024 (USD Mn)
TABLE 9. Global cell line development market, by application, 2013 - 2024 (USD Mn)
TABLE 10. Global cell line development market, by application, 2013 - 2024 (USD Mn)
TABLE 11. Global cell line development market, by region, 2013 - 2024 (USD Million)
TABLE 12. Industry impact forces
TABLE 13. Reagents and media market by region, 2013 - 2024 (USD Million)
TABLE 14. Equipment market, by region, 2013 - 2024, (USD Million)
TABLE 15. Incubators market, by region, 2013 - 2024, (USD Million)
TABLE 16. Centrifuges market, by region, 2013 - 2024, (USD Million)
TABLE 17. Bioreactors market, by region, 2013 - 2024, (USD Million)
TABLE 18. Storage equipment market, by region, 2013 - 2024, (USD Million)
TABLE 19. Microscopes market, by region, 2013 - 2024, (USD Million)
TABLE 20. Accessories and consumables market, by region, 2013 - 2024, (USD Million)
TABLE 21. Mammalian cell line development market, by region, 2013 - 2024, (USD Million)
TABLE 22. Non-mammalian cell development market, by region 2013 - 2024, (USD Million)
TABLE 23. Insect cell line development market, by region 2013 - 2024, (USD Million)
TABLE 24. Amphibians cell line development market, by region 2013 - 2024, (USD Million)
TABLE 25. Recombinant cell line development market, by region, 2013 - 2024, (USD Million)
TABLE 26. Hybridomas cell line development market, by region, 2013 - 2024, (USD Million)
TABLE 27. Continuous cell line development market, by region, 2013 - 2024, (USD Million)
TABLE 28. Primary cell line development market, by region, 2013 - 2024, (USD Million)
TABLE 29. Bioproduction market, by region, 2013 - 2024, (USD Million)
TABLE 30. Drug discovery market, by region, 2013 - 2024, (USD Million)
TABLE 31. Toxicity testing market, by region, 2013 - 2024, (USD Million)
TABLE 32. Tissue engineering market, by region, 2013 - 2024, (USD Million)
TABLE 33. Research market, by region, 2013 - 2024, (USD Million)
TABLE 34. North America cell line development market, by country 2013 - 2024 (USD Million)
TABLE 35. North America cell line development market, by product, 2013 - 2024 (USD Million)
TABLE 36. North America cell line development market, by equipment, 2013 - 2024 (USD Million)
TABLE 37. North America cell line development market, by source, 2013 - 2024 (USD Million)
TABLE 38. North America cell line development market, by non-mammalian source 2013 - 2024 (USD Million)
TABLE 39. North America cell line development market, by type of cell lines, 2013 - 2024 (USD Million)
TABLE 40. North America cell line development market, by application, 2013 - 2024 (USD Million)
TABLE 41. U.S. cell line development market, by product, 2013 - 2024 (USD Million)
TABLE 42. U.S. cell line development market, by equipment, 2013 - 2024 (USD Million)
TABLE 43. U.S. cell line development market, by source, 2013 - 2024 (USD Million)
TABLE 44. U.S. cell line development market, by non-mammalian source 2013 - 2024 (USD Million)
TABLE 45. U.S. cell line development market, by type of cell lines, 2013 - 2024 (USD Million)
TABLE 46. U.S. cell line development market, by application, 2013 - 2024 (USD Million)
TABLE 47. Canada cell line development market, by product, 2013 - 2024 (USD Million)
TABLE 48. Canada cell line development market, by equipment, 2013 - 2024 (USD Million)
TABLE 49. Canada cell line development market, by source, 2013 - 2024 (USD Million)
TABLE 50. Canada cell line development market, by non-mammalian source 2013 - 2024 (USD Million)
TABLE 51. Canada cell line development market, by type of cell lines, 2013 - 2024 (USD Million)
TABLE 52. Canada cell line development market, by application, 2013 - 2024 (USD Million)
TABLE 53. Europe cell line development market, by country 2013 - 2024 (USD Million)
TABLE 54. Europe cell line development market, by product, 2013 - 2024 (USD Million)
TABLE 55. Europe cell line development market, by equipment, 2013 - 2024 (USD Million)
TABLE 56. Europe cell line development market, by source, 2013 - 2024 (USD Million)
TABLE 57. Europe cell line development market, by non-mammalian source 2013 - 2024 (USD Million)
TABLE 58. Europe cell line development market, by type of cell lines, 2013 - 2024 (USD Million)
TABLE 59. Europe cell line development market, by application, 2013 - 2024 (USD Million)
TABLE 60. Germany cell line development market, by product, 2013 - 2024 (USD Million)
TABLE 61. Germany cell line development market, by equipment, 2013 - 2024 (USD Million)
TABLE 62. Germany cell line development market, by source, 2013 - 2024 (USD Million)
TABLE 63. Germany cell line development market, by non-mammalian source 2013 - 2024 (USD Million)
TABLE 64. Germany cell line development market, by type of cell lines, 2013 - 2024 (USD Million)
TABLE 65. Germany cell line development market, by application, 2013 - 2024 (USD Million)
TABLE 66. France cell line development market, by product, 2013 - 2024 (USD Million)
TABLE 67. France cell line development market, by equipment, 2013 - 2024 (USD Million)
TABLE 68. France cell line development market, by source, 2013 - 2024 (USD Million)
TABLE 69. France cell line development market, by non-mammalian source 2013 - 2024 (USD Million)
TABLE 70. France cell line development market, by type of cell lines, 2013 - 2024 (USD Million)
TABLE 71. France cell line development market, by application, 2013 - 2024 (USD Million)
TABLE 72. UK cell line development market, by product, 2013 - 2024 (USD Million)
TABLE 73. UK cell line development market, by equipment, 2013 - 2024 (USD Million)
TABLE 74. UK cell line development market, by source, 2013 - 2024 (USD Million)
TABLE 75. UK cell line development market, by non-mammalian source 2013 - 2024 (USD Million)
TABLE 76. UK cell line development market, by type of cell lines, 2013 - 2024 (USD Million)
TABLE 77. UK cell line development market, by application, 2013 - 2024 (USD Million)
TABLE 78. Spain cell line development market, by product, 2013 - 2024 (USD Million)
TABLE 79. Spain cell line development market, by equipment, 2013 - 2024 (USD Million)
TABLE 80. Spain cell line development market, by source, 2013 - 2024 (USD Million)
TABLE 81. Spain cell line development market, by non-mammalian source 2013 - 2024 (USD Million)
TABLE 82. Spain cell line development market, by type of cell lines, 2013 - 2024 (USD Million)
TABLE 83. Spain cell line development market, by application, 2013 - 2024 (USD Million)
TABLE 84. Italy cell line development market, by product, 2013 - 2024 (USD Million)
TABLE 85. Italy cell line development market, by equipment, 2013 - 2024 (USD Million)
TABLE 86. Italy cell line development market, by source, 2013 - 2024 (USD Million)
TABLE 87. Italy cell line development market, by non-mammalian source 2013 - 2024 (USD Million)
TABLE 88. Italy cell line development market, by type of cell lines, 2013 - 2024 (USD Million)
TABLE 89. Italy cell line development market, by application, 2013 - 2024 (USD Million)
TABLE 90. Russia cell line development market, by product, 2013 - 2024 (USD Million)
TABLE 91. Russia cell line development market, by equipment, 2013 - 2024 (USD Million)
TABLE 92. Russia cell line development market, by source, 2013 - 2024 (USD Million)
TABLE 93. Russia cell line development market, by non-mammalian source 2013 - 2024 (USD Million)
TABLE 94. Russia cell line development market, by type of cell lines, 2013 - 2024 (USD Million)
TABLE 95. Russia cell line development market, by application, 2013 - 2024 (USD Million)
TABLE 96. Asia Pacific cell line development market, by country, 2013 - 2024 (USD Million)
TABLE 97. Asia Pacific cell line development market, by product, 2013 - 2024 (USD Million)
TABLE 98. Asia Pacific cell line development market, by equipment, 2013 - 2024 (USD Million)
TABLE 99. Asia Pacific cell line development market, by source, 2013 - 2024 (USD Million)
TABLE 100. Asia Pacific cell line development market, by non-mammalian source 2013 - 2024 (USD Million)
TABLE 101. Asia Pacific cell line development market, by type of cell lines, 2013 - 2024 (USD Million)
TABLE 102. Asia Pacific cell line development market, by application, 2013 - 2024 (USD Million)
TABLE 103. Japan cell line development market, by product, 2013 - 2024 (USD Million)
TABLE 104. Japan cell line develop

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report